ACHV Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit. Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. ACHV has surged 173% over 52 weeks. Shares recently hit a 3-year high earlier in July. Despite robust technicals, ACHV remains highly speculative, as it has not yet begun monetizing... | ||
 Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting Achieve Life Sciences (NASDAQ:ACHV) held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company’s Chief Legal Officer, would act as secretary and r | ||